AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00391729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take placebo QD, BID for 4-6 weeks
Study NCT02699593 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test Contact Lens
Study NCT02699593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Contact Lens
Study NCT02699593 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Contact Lens
Study NCT02699593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Contact Lens
Study NCT04246697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol
Description: Used for both arms, scheduled
Study NCT04246697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Used for both arms PRN
Study NCT04246697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Used for both arms PRN
Study NCT04246697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Used for both arms PRN
Study NCT04246697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Used for both arms PRN
Study NCT04246697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Used for Arm B
Study NCT04246697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toradol
Description: Used for Arm B
Study NCT04246697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Used for Arm B - anesthesia block
Study NCT00097253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to relaxant and stimulant odors
Description: A yellow-tinted cotton ball containing 100 ml of the essential oil or distilled water was taped between the nose and upper lip on top of a piece of surgical tape; use of the barrier tape avoided percutaneous absorption . This method provided continuous and uniform exposure across subjects that would not have been possible with ambient room inhalation, and helped maintain experimenter blindness.
Study NCT00097253 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exposure to relaxant and stimulant odors
Description: A yellow-tinted cotton ball containing 100 ml of the essential oil or distilled water was taped between the nose and upper lip on top of a piece of surgical tape; use of the barrier tape avoided percutaneous absorption . This method provided continuous and uniform exposure across subjects that would not have been possible with ambient room inhalation, and helped maintain experimenter blindness.
Study NCT03608670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defibrillation using the Extravascular ICD
Description: VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
Study NCT00904527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation (Schultz)
Description: Patients have relaxation consultations during 2 months
Study NCT00702429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Analysis of the PNN, analysis of the monocytes
Study NCT00702429 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood sampling
Description: Analysis of the PNN, analysis of the monocytes
Study NCT02186405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEVOTHYROXINE
Description: administration of levothyroxine
Study NCT01253499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRx0037
Description: 75mg and 100mg tablets used to create doses of 100mg and 175mg. Active placebo 2mg and blank placebo used as comparators.
Study NCT01407900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CD-NP
Description: CD-NP as a four hour infusion at 10 ng/kg/min IV
Study NCT01407900 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Dextrose in Water
Description: four hour infusion IV
Study NCT01884389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Home-based medical and social support services, as an extension of and collaboration with primary care services provided. Phone calls and visits scheduled based on patient's level of need. Communication with primary care team via navigation plan faxed / emailed as needed. Volunteers will also be matched with intervention patients to provide additional support services by phone / in-person visits.
Study NCT01304394 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ped3CB
Description: The Ped3CB is a ready to use, triple-chamber bag containing a sterile, nonpyrogenic combination of amino acids (Primene®, Baxter) with electrolytes, glucose, and lipids (ClinOleic®, Baxter) in separate compartments for intravenous (IV) PN. The dosage, frequency and duration is dependent on patient's weight, age, clinical status as well as addition energy or protein given enterally/orally.
Study NCT01693965 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sputum samples
Study NCT00744250 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pancrelipase
Description: PANCRECARB MS-16
Study NCT03255772 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetocardiography
Description: Study subjects will be placed within a magnetic shielding apparatus. Noninvasive sensors placed over the subject's torso will acquire magnetic field fluctuations generated by cardiac activity, which will then be analyzed for evidence of myocardial ischemia.
Study NCT02205151 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan
Study NCT02205151 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amlodipine
Study NCT02205151 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan/Amlodipine combination
Study NCT02628691 — intervention group
Intervention type: OTHER
Intervention: Liver fibrosis progression
Description: A history taking and physical examination focused on hepatic disease and blood sampling for basic hematologic and hepatic function parameters will be performed. Patients will also be referred every year for ultrasound and transient elastography measurements and sampling for some additional liver function tests and measurement of HCV-RNA viral load.
Study NCT00913328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast (Singulair)
Description: 10 mg tablet once daily
Study NCT00913328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo once daily
Study NCT04904757 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Contrast-enhanced spectral mammography (CESM)
Description: CESM is a mammogram performed after the injection of IV contrast. CESM is used most often when additional information is needed after a standard mammogram. CESM has also been used to determine the extent of a known breast cancer, to screen patients at high risk for developing breast cancer due to a family history or positive cancer genes, and for women with dense breast tissue. Two images are taken almost at the same time during the exam, after the iodine based contrast injection is administered. The first image is comparable to a regular mammogram. The second image shows areas that take up the contrast (enhance) showing increased blood flow. Breast cancers often enhance with contrast due to a greater amount of blood vessels. Non-cancerous lesions can also have greater blood flow.
Study NCT04034758 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Quantitative multi-donor Intestinal Microbiota Capsule (SQIMC-md)
Description: heterologous fecal microbiota transplantation (FMT) by Standardized Quantitative multi-donor Intestinal Microbiota Capsule (SQIMC-md)
Study NCT04034758 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule
Description: Oral administration of 30 placebo capsule containing edible pigmented starch
Study NCT00580801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Telaprevir 750 milligram (mg) tablet will be administered three times a day orally for 2 weeks.
Study NCT00580801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated-interferon-alfa-2a
Description: Pegylated-interferon-alfa-2a (180 microgram \[mcg\] subcutaneous injection, once weekly) will be administered from Week 1 to Week 48 or 50.
Study NCT00580801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon-alfa-2a
Description: Pegylated-interferon-alfa-2a (180 microgram \[mcg\] subcutaneous injection, once weekly) will be administered from Week 1 to Week 48 or 50.
Study NCT00580801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet to telaprevir was administered three times a day orally for 2 weeks.
Study NCT00580801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin (1000-1200 mg as oral tablet daily) will be administered from Week 1 to Week 48 or 50.
Study NCT00580801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin (1000-1200 mg as oral tablet daily) will be administered from Week 1 to Week 48 or 50.
Study NCT00191269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
Study NCT00191269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
Study NCT02664337 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision tool
Description: A survey will be created for each condition that reflects the most important aspects of the corresponding treatment process.
Study NCT02664337 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment information
Description: Participants will receive information pertaining to one of the 12 specified musculoskeletal conditions. This information will reflect information commonly distributed to patients seeking to make a decision concerning treatment for their condition.
Study NCT01877616 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: diagnostic test
Description: Polysomnography
Study NCT01877616 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diagnostic test
Description: overnight polysomnography
Study NCT00542386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-196
Description: 3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
Study NCT00542386 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
Study NCT03052946 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bulking agent
Description: Filling bulking agent in the anal canal
Study NCT03052946 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endoanal electrostimulation
Description: The technique used will be with a frequency of 30 to 40 Hz with pulse width of 200 ms with maximum intensity of 800mAmp and duration of 30 minutes
Study NCT00614406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex
Description: One 400mg tablet daily.
Study NCT00614406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet daily.
Study NCT00310401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: 5 mg nebulized q4h
Study NCT00310401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol
Description: 5 mg nebulized q4h
Study NCT00310401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 1.0 cc diluted with saline in identical fashion to study drug and administered by nebulizer every 4 hours
Study NCT00820118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Structured treatment interruption
Description: The preferentially recommended treatment of the study is atazanavir boosted with ritonavir, associated with a fixed combination of abacavir and lamivudine or emtricitabine + tenofovir~Usual dosage recommended :~* atazanavir : 300 mg/d~* ritonavir : 100 mg/d~* abacavir 600 mg and lamivudine 300 mg : once a day~* tenofovir 245 mg and emtricitabine 200 mg : once a day
Study NCT02561403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EVO multitask video game
Description: Participants will play a multitasking game for 4 weeks
Study NCT02561403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EVO words video game
Description: Participants will play a word puzzle game for 4 weeks
Study NCT00477100 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood, tissue, and stool
Study NCT00477100 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Participate in interview
Study NCT00477100 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Undergo collection of medical data
Study NCT00477100 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary Studies
Study NCT01850992 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active CPAP
Description: Effective CPAP will be administered
Study NCT01850992 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham CPAP
Description: This is placebo CPAP
Study NCT01923948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: One 150 mg oral dose of Pregabalin given before surgery
Study NCT01923948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Pregabalin)
Description: One oral dose of placebo given before surgery
Study NCT01887041 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stent
Description: Endoscopically inserted biliary tract drainage
Study NCT01887041 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biliodigestive anastomosis
Description: Biliodigestive anastomosis
Study NCT00004192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00004192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Study NCT00004192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00004192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00004192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT02566525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb
Description: Cytosorb device use during cardiopulmonary bypass
Study NCT00004192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Study NCT02952950 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Oralstimulation
Description: The intervention group granted in total 1 hour instructions in a program of oral stimulation by one of two occupational therapists with experience in oral stimulation of preterm infants. The first guidance for parents has duration of approximately half an hour and then follow-up once or twice, depending on the needs of the family. To maintain consistent intervention over time is the program of oral stimulation written in a script, where the family also must record the following variables: date and time of oral stimulation. In occupational therapy the guidance and in the script examines the signs that the infant exhibits when it is ready / not ready for stimulation. The family also sees a movie where these signs and the program of oral stimulation review auditory and visual.
Study NCT01043549 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Repetitive transcranial stimulation of the posterior parietal cortex
Study NCT01201785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: After having been on aspirin 81mg/daily for at least one-week, patients switched their aspirin regimen on a weekly basis according to the following scheme: aspirin 81mg twice daily (bid) for one week; aspirin 162 mg once daily (od) for one week; aspirin 162 mg bid for one week; aspirin 325 mg od for one week. Pharmacodynamic assessments were made after each sequence (5 time-points). Afterward, patients resumed the dose of aspirin that they were on prior to entering the study.
Study NCT01043549 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Repetitive transcranial stimulation of the posterior parietal cortex
Study NCT01191788 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Cognitive Behavioral Therapy
Description: 16 two hour sessions of group CBT
Study NCT01191788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy
Description: 16 two hour sessions of group CBT
Study NCT01191788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CBT for Depression
Description: 16 of group CBT for depression delivered in 2 hour groups for up to 8 weeks by a trained substance abuse treatment counselor
Study NCT03478501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: This intervention is a tablet based Lethal Means Decision Aid with proposed use to augment lethal means counseling in emergency departments for patients at risk of suicide.
Study NCT01959412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 27.5 mcg
Description: indacaterol 27.5 mcg twice daily inhaled once via inhaler
Study NCT01959412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 37.5
Description: Indacaterol 37.5 mcg once daily, inhaled once via inhaler
Study NCT01959412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 55 mcg
Description: Indacaterol 55 mcg once daily, inhaled once via inhaler
Study NCT01959412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 75 mcg
Description: Indacaterol 75 mcg once daily, inhaled once via inhaler
Study NCT01959412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 mcg
Description: Indacaterol 150 mcg once daily, inhaled once via inhaler
Study NCT01959412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol once or twice daily (depending on assigned sequence) via inlaher
Study NCT03018600 — intervention group
Intervention type: BEHAVIORAL
Intervention: diet and exercise intervention
Description: consult nutrious doctors giving specific food and take regular exercise when under steroid therapy
Study NCT03834753 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 1.25 mg, intravitreal injection
Study NCT03834753 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 0.5mg, intravitreal injection
Study NCT01353092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Re5 Pulsating ElectroMagnetic Fields
Description: Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF):~30 minutes of active PEMF therapy in the morning and 30 minutes of active PEMF therapy in the afternoon
Study NCT01353092 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Re5 Pulsating ElectroMagnetic Fields (PEMF)
Description: Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF):~30 minutes of sham therapy and 30 minutes of active therapy (morning or afternoon)
Study NCT00295867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Zoledronic acid is a new, highly potent, heterocyclic nitrogen-containing third generation bisphosphonate that has demonstrated 40- to 850- fold greater potency than pamidronate in preclinical models of bone resorption. The mechanism of action of nitrogen-containing bisphosphonates such as pamidronate and zoledronic acid appears to involve inhibition of the mevalonate pathway
Study NCT02225600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40 IU Intranasal Oxytocin
Description: 40 IU intranasal oxytocin
Study NCT02225600 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 40 IU Intranasal Oxytocin
Description: 40 IU intranasal oxytocin
Study NCT02225600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Intranasal Placebo
Study NCT02225600 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Intranasal Placebo
Study NCT02225600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 24 IU intranasal Oxytocin
Study NCT02225600 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 24 IU intranasal Oxytocin
Study NCT02271607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: moxibustion
Description: The treatment schedule is three times per week for four weeks. Indirect moxa pillars and indirect-container moxibustion will be used.